Arianna Zangrilli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Pilot validation of the genital psoriasis reported outcomes questionnaire in an Italian cohort.

Pilot validation of the genital psoriasis reported outcomes questionnaire in an Italian cohort.

Journal: Frontiers in medicine

Published: February 23, 2026

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Journal: Clinics and practice

Published: November 19, 2025

Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience.

Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience.

Journal: Psoriasis (Auckland, N.Z.)

Published: January 12, 2025

Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.

Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.

Journal: Dermatology practical & conceptual

Published: December 27, 2024

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.

Journal: Dermatology practical & conceptual

Published: August 28, 2024

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region.

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region.

Journal: Dermatology practical & conceptual

Published: March 14, 2024

Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.

Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.

Journal: International journal of dermatology

Published: January 17, 2024

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.

Journal: Drugs in context

Published: January 31, 2023

Improvement of Psoriasis Using Oral Probiotic Streptococcus salivarius K-12: a Case-Control 24-Month Longitudinal Study.

Improvement of Psoriasis Using Oral Probiotic Streptococcus salivarius K-12: a Case-Control 24-Month Longitudinal Study.

Journal: Probiotics and antimicrobial proteins

Published: April 04, 2022

Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Journal: Dermatologic therapy

Published: December 05, 2021

A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.

A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 19, 2021

Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.

Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.

Journal: Expert opinion on biological therapy

Published: July 19, 2021

Showing 1-12 of 45

Last Updated: 09/26/2026